John M. L. Ebos

Genitourinary Section, Roswell Park Cancer Institute

Affiliated withRoswell Park Cancer Institute

Research Area

Biography

John M. L. Ebos has not added Biography.
If you are John M. L. Ebos and would like to personalize this page please email our Author Liaison for assistance.

JoVE Journal Publications

ArticleTotal : 1	Year
Publication title Cited by 23	2014

Other Publications

Article	Year
Imatinib mesylate (STI-571) reduces Bcr-Abl-mediated vascular endothelial growth factor secretion in chronic myelogenous leukemia. Molecular cancer research : MCR\| PubMed ID: 12496355	2002
Dok-R binds c-Abl and regulates Abl kinase activity and mediates cytoskeletal reorganization. The Journal of biological chemistry\| PubMed ID: 12777393	2003
A naturally occurring soluble form of vascular endothelial growth factor receptor 2 detected in mouse and human plasma. Molecular cancer research : MCR\| PubMed ID: 15235107	2004
Increased plasma vascular endothelial growth factor (VEGF) as a surrogate marker for optimal therapeutic dosing of VEGF receptor-2 monoclonal antibodies. Cancer research\| PubMed ID: 15374976	2004
Down-regulation of DNA mismatch repair proteins in human and murine tumor spheroids: implications for multicellular resistance to alkylating agents. Molecular cancer therapeutics\| PubMed ID: 16227397	2005
Cellular and molecular surrogate markers to monitor targeted and non-targeted antiangiogenic drug activity and determine optimal biologic dose. Current cancer drug targets\| PubMed ID: 16305351	2005
Multiple circulating proangiogenic factors induced by sunitinib malate are tumor-independent and correlate with antitumor efficacy. Proceedings of the National Academy of Sciences of the United States of America\| PubMed ID: 17942672	2007
Vascular endothelial growth factor-mediated decrease in plasma soluble vascular endothelial growth factor receptor-2 levels as a surrogate biomarker for tumor growth. Cancer research\| PubMed ID: 18199548	2008
Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis. Cancer cell\| PubMed ID: 19249681	2009
Dose-dependent increases in circulating TGF-alpha and other EGFR ligands act as pharmacodynamic markers for optimal biological dosing of cetuximab and are tumor independent. Clinical cancer research : an official journal of the American Association for Cancer Research\| PubMed ID: 19276250	2009
Tumor and host-mediated pathways of resistance and disease progression in response to antiangiogenic therapy. Clinical cancer research : an official journal of the American Association for Cancer Research\| PubMed ID: 19671869	2009
Peering into the aftermath: The inhospitable host? Nature medicine\| PubMed ID: 20930748	2010
Antiangiogenic therapy: impact on invasion, disease progression, and metastasis. Nature reviews. Clinical oncology\| PubMed ID: 21364524	2011
Mind the gap: potential for rebounds during antiangiogenic treatment breaks. Clinical cancer research : an official journal of the American Association for Cancer Research\| PubMed ID: 22679177	2012
Preclinical recapitulation of antiangiogenic drug clinical efficacies using models of early or late stage breast cancer metastatis. Breast (Edinburgh, Scotland)\| PubMed ID: 24074794	2013